A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST) (EAST)
A Real-world, Prospective, Observational Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)
Sponsor: AbbVie
Listed as NCT03505892, this observational or N/A phase trial focuses on Ankylosing Spondylitis (AS) and remains completed. Sponsored by AbbVie, it has been updated 13 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Aug 2023 — Jul 2024 [monthly]
Completed
-
Dec 2021 — Aug 2023 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jan 2021 — Dec 2021 [monthly]
Active Not Recruiting
▶ Show 8 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jul 2020 — Oct 2020 [monthly]
Recruiting
-
Jul 2019 — Jul 2020 [monthly]
Recruiting
-
Nov 2018 — Jul 2019 [monthly]
Recruiting
-
Aug 2018 — Nov 2018 [monthly]
Recruiting
-
Jul 2018 — Aug 2018 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .